Entrada Therapeutics (TRDA) Stock Forecast: StockMap's 2-Week Call

TRDA stock forecast: StockMap's model leans Underperform on Entrada Therapeutics for the two weeks after the Nov 19 close, toward TRDA trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 6 two-week windows on TRDA since Aug 24; by chance, a call on the same dates was right 59% of the time.

Entrada Therapeutics last closed at $4.64, -7.75% on the session.

Against the IVW growth benchmark the position is -5.42% over the forecast window.

Entrada Therapeutics' market cap is $181.66M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -21 (too close to call).

Where TRDA sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

42 daily calls for TRDA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Entrada Therapeutics in the 15th percentile on return on equity, where 100 is best.

Entrada Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Entrada Therapeutics as the 242nd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Entrada Therapeutics ranks 171st of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Entrada Therapeutics (TRDA) — StockMap 2-week forecast & tracked accuracy